Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panblok H7+MF59 influenza vaccine in adults
NCT05608005Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Panblok H7 in influenza (3 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean of Hemagglutination Inhibition Antibody Titer at Day 22, Geometric Mean of Hemagglutination Inhibition Antibody Titer at Day 43 and 31 more. Started Nov 2022; status: completed.
02
Drugs
Panblok H7
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05608005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608005.